Emilio Francesco Giunta

28PUBLICATIONS
94CO-AUTHORS
Predictive and prognostic markersRadiation therapySolid tumoursPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Sep 11, 2026
Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy.

|Mar 13, 2026
Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.

Sara Bleve, Francesco Ravera, Silvia Rodrigues

|Nov 27, 2025
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.

Irene Marini, Emilio Francesco Giunta, Silvia Nicolini

|Oct 22, 2025
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.

Thomas Powles, Ariel G Kann, Daniel Castellano

|Oct 13, 2025
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer.

Nicole Brighi, Daniel Wetterskog, Osvaldas Vainauskas

|Jan 27, 2025
Rare epithelial gastric cancers: a review of the current treatment knowledge.

Angelica Petrillo, Margaret Ottaviano, Luca Pompella

Pageof 5

Frequent Collaborators

7 joint publications

Bruno Daniele

6 joint publications

Ugo De Giorgi

5 joint publications

Angelica Petrillo

5 joint publications

Margaret Ottaviano